08/203004		was	washington, D.C. 20231		
SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.	
08/203.	004 02/28/	94 BERD	·	D 1225/0062	
DARBY & DARBY PC 805 THIRD AVENUE NEW YORK NY 10022		HM22/0705	EXAMINER		
			ART UNIT	NGAR S PAPER NUMBER	
			1647	42	
	1		DATE MAILED:	۷ 07/05/01	

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS
ADVISORY ACTION
THE PERIOD FOR RESPONSE:
a) is extended to run or continues to run from the date of the final rejection
b) expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.
Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.
Appellant's Brief is due in accordance with 37 CFR 1.192(a).
pplicant's response to the final rejection, filed Jule 2,200/ has been considered with the following effect, but it is not deemed to place the application in condition for allowance:
1. The proposed amendments to the claim and /or specification will not be entered and the final rejection stands because:
 a. There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.
b. They raise new issues that would require further consideration and/or search. (See Note).
c. They raise the issue of new matter. (See Note).
d. They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.
e. They present additional claims without cancelling a corresponding number of finally rejected claims.
NOTE:
Newly proposed or amended claimswould be allowed if submitted in a second St.
the non-allowable claims. The non-Earlies of the south a separately filed amendment cancelling
be as follows:
Claims allowed:Dare_
Claims objected to: USU 4
Claims rejected: 43, 44, 47, 49-62, 61-72 + 74-77 However:
Applicant's response has overcome the following rejection(s): Lyection of C143 49-51, 54-55 UNOTA 112 154
The affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because
The affidavit or exhibit will not be considered because applicant has not shown good and sufficent reasons why it was not earlier presented.
The proposed drawing correction ☐ has ☐ has not been approved by the examiner.
Other Lucies Lucies
SUSAN UNGAR/PH.D PRIMARY EXAMINER

PTOL-303 (REV. 5-89)

Serial No: 08/203,004

Art Unit: 1642

1. The Amendment After-Final filed June 2, 2001 (Paper No. 46) in response to the Office Action of November 29, 2000 (Paper No. 44) is acknowledged and has been entered. Previously pending claims 43 and 47 have been amended. Claims 43, 44, 47, 49-62, 64-72 and 74-77 are currently being examined.

Claim Rejections - 35 USC § 103

2. Claims 47, 65-72 and 74-77 remain rejected under 35 USC 103 for the reasons previously set forth in Paper No. 36, Sections 10-11, pages 8-15, Paper No. 41, Sections 5-6, pages 2-4 and in Paper No. 44, Sections 5 and 6, pages 3-5.

Applicant argues that (a) Examiner gives more weight to the Berd '89 abstract than one of ordinary skill at the time the invention would have given it and the Braun Declaration sets forth that Berd '89 does not describe a successful immunotherapy for melanoma, (b) Applicant details the three basic criteria that must be met to establish a *prima facie* case for obviousness under 35 USC 103 and states that since Berd '89 fails to provide any expectation of success the reference is completely irrelevant and no other reference provided makes up for this flaw, (c) Applicant reiterates the deficiencies of Murphy, Berd '89 Geczy and Antibody Patents and the combination thereof. The arguments have been considered but have not been found persuasive (a') for the reasons previously set forth in Paper No. 41, Section 7, pages 4-5. The Braun Declaration has not been considered because Applicant has not shown good and sufficient reasons why it was not earlier presented, (b') the Berd '89 reference is not irrelevant for the reasons set forth previously and above, (c') the arguments are not persuasive for the reasons previously set forth

Serial No: 08/203,004 Page 3

Art Unit: 1642

3. Claims 43, 44, 47, 49-62, 64-72, and 74-77 remain rejected under 35 USC 103 for the reasons previously set forth in Paper No. 36, Section 12, pages 15-18, Paper No. 41, Section 7, pages 4-5 and in Paper No. 44, Section 7, pages 5-6.

Applicant reiterates the arguments drawn to Wiseman and the arguments drawn to the combination of Berd '89, The Antibody Patents and Geczy. The arguments have been considered but have not been found persuasive for the reasons previously set forth.

4. Claims 43, 44, 47, 49-62, 64-72, and 74-77 remain rejected under 35 USC 103 for the reasons previously set forth in Paper No. 36, Section 13, pages 18-21, Paper No. 41, Section 8, page 6 and in Paper No. 44, Section 8, page 6.

Applicant reiterates arguments drawn to Berd '83. The arguments have been considered but have not been found persuasive for the reasons previously set forth in Paper Nos 36, 41 and 44.

5. Claims 43, 44, 47, 49-62, 64-72, and 74-77 remain rejected under 35 USC 103 for the reasons previously set forth in Paper No. 36, Section 14, pages 21-25, Paper No. 41, Section 9, page 7 and in Paper No. 44, Section 9, page 7.

Applicant reiterates the arguments previously set forth. The arguments have been considered but have not been found persuasive for the reasons previously set forth in Paper Nos 36, 41 and 44.

6. All other objections and rejections recited in Paper No. 44 are withdrawn.

SUSAN UNGAR, PH.D PRIMARY EXAMINER